# Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants

> **NCT04971395** · PHASE1 · COMPLETED · sponsor: **Xentria, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Placebo
- **DRUG:** XTMAB-16 2 mg/kg
- **DRUG:** XTMAB-16 4mg/kg

## Key facts

- **NCT ID:** NCT04971395
- **Lead sponsor:** Xentria, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-25
- **Primary completion:** 2022-03-18
- **Final completion:** 2022-03-18
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04971395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04971395, "Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04971395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*